No annual revenue total was found in CNS Pharmaceuticals, Inc.'s SEC filings.
CNS Pharmaceuticals, Inc. (CNSP) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$13.8 million.
Revenue
—
Net income (TTM)
$-16.70M
-8.0% vs year-ago TTM
Operating cash flow (TTM)
$-13.41M
+35.7% vs year-ago TTM
Free cash flow
$-13.83M
+19.2% vs prior year
EPS (TTM)
$-7.72
+91.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
811,449
+0.0% vs prior year
Net cash
$13.56M
FY 2020
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNSP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1729427
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$16.0M | -$14.9M | -$18.9M | -$15.3M | -$14.5M |
| Net income | -$15.9M | -$14.9M | -$18.9M | -$15.3M | -$14.5M |
| Diluted EPS | -$35.75 | -$466.89 | -$12,509.11 | -$11.22 | — |
| Operating cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | -$13.5M |
| Free cash flow | -$13.8M | -$17.1M | -$14.1M | -$10.6M | — |
| Total assets | $8.6M | $8.7M | $1.7M | $13.1M | $8.8M |
| Total liabilities | $4.1M | $2.5M | $6.1M | $4.9M | $2.6M |
| Stockholders' equity | $4.5M | $6.2M | -$4.4M | $8.1M | $6.2M |
| Cash and investments | $7.2M | $6.5M | $548,721 | $10.1M | $5.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 2, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jul 2, 2026 | Jul 2, 2026 |
| 10-Q | Quarterly report | May 14, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Officer or director change
|
May 4, 2026 | May 4, 2026 |
| 10-K/A | Amended annual report | Apr 30, 2026 | Dec 31, 2025 |
All 390 CNS Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.